vs

Side-by-side financial comparison of SANFILIPPO JOHN B & SON INC (JBSS) and Tilray Brands, Inc. (TLRY). Click either name above to swap in a different company.

SANFILIPPO JOHN B & SON INC is the larger business by last-quarter revenue ($314.8M vs $217.5M, roughly 1.4× Tilray Brands, Inc.). SANFILIPPO JOHN B & SON INC runs the higher net margin — 5.7% vs -20.7%, a 26.4% gap on every dollar of revenue. On growth, SANFILIPPO JOHN B & SON INC posted the faster year-over-year revenue change (4.6% vs 3.1%). Over the past eight quarters, SANFILIPPO JOHN B & SON INC's revenue compounded faster (7.6% CAGR vs 7.5%).

John B. Sanfilippo & Son Inc. (JBSS) is a leading US processor, marketer and distributor of high-quality tree nuts, peanuts, dried fruits, and value-added snack products. It serves retail, foodservice, and industrial ingredient customers primarily across North America, offering both branded and private label product lines.

Tilray Brands, Inc. is an American pharmaceutical, cannabis-lifestyle and consumer packaged goods company, incorporated in the United States, headquartered in New York City. Tilray also has operations in Canada, Australia, New Zealand, and Latin America, with growing facilities in Germany and Portugal.

JBSS vs TLRY — Head-to-Head

Bigger by revenue
JBSS
JBSS
1.4× larger
JBSS
$314.8M
$217.5M
TLRY
Growing faster (revenue YoY)
JBSS
JBSS
+1.4% gap
JBSS
4.6%
3.1%
TLRY
Higher net margin
JBSS
JBSS
26.4% more per $
JBSS
5.7%
-20.7%
TLRY
Faster 2-yr revenue CAGR
JBSS
JBSS
Annualised
JBSS
7.6%
7.5%
TLRY

Income Statement — Q2 FY2026 vs Q2 FY2026

Metric
JBSS
JBSS
TLRY
TLRY
Revenue
$314.8M
$217.5M
Net Profit
$18.0M
$-44.9M
Gross Margin
18.8%
26.4%
Operating Margin
8.3%
-10.2%
Net Margin
5.7%
-20.7%
Revenue YoY
4.6%
3.1%
Net Profit YoY
32.1%
47.4%
EPS (diluted)
$1.53
$-0.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
JBSS
JBSS
TLRY
TLRY
Q4 25
$314.8M
$217.5M
Q3 25
$298.7M
$209.5M
Q2 25
$269.1M
$224.5M
Q1 25
$260.9M
$185.8M
Q4 24
$301.1M
$210.9M
Q3 24
$276.2M
$200.0M
Q2 24
$269.6M
$229.9M
Q1 24
$271.9M
$188.3M
Net Profit
JBSS
JBSS
TLRY
TLRY
Q4 25
$18.0M
$-44.9M
Q3 25
$18.7M
$-322.0K
Q2 25
$13.5M
$-1.3B
Q1 25
$20.2M
$-789.4M
Q4 24
$13.6M
$-85.3M
Q3 24
$11.7M
$-39.2M
Q2 24
$10.0M
$-31.7M
Q1 24
$13.5M
$-92.7M
Gross Margin
JBSS
JBSS
TLRY
TLRY
Q4 25
18.8%
26.4%
Q3 25
18.1%
27.4%
Q2 25
18.1%
30.1%
Q1 25
21.4%
28.0%
Q4 24
17.4%
29.0%
Q3 24
16.9%
29.8%
Q2 24
18.5%
35.8%
Q1 24
18.1%
26.2%
Operating Margin
JBSS
JBSS
TLRY
TLRY
Q4 25
8.3%
-10.2%
Q3 25
9.0%
1.0%
Q2 25
7.5%
-643.1%
Q1 25
10.8%
-409.0%
Q4 24
6.4%
-20.0%
Q3 24
6.2%
-18.3%
Q2 24
5.4%
-7.2%
Q1 24
6.7%
-43.6%
Net Margin
JBSS
JBSS
TLRY
TLRY
Q4 25
5.7%
-20.7%
Q3 25
6.3%
-0.2%
Q2 25
5.0%
-566.9%
Q1 25
7.7%
-424.9%
Q4 24
4.5%
-40.5%
Q3 24
4.2%
-19.6%
Q2 24
3.7%
-13.8%
Q1 24
5.0%
-49.2%
EPS (diluted)
JBSS
JBSS
TLRY
TLRY
Q4 25
$1.53
$-0.41
Q3 25
$1.59
$0.00
Q2 25
$1.15
$7.26
Q1 25
$1.72
$-8.69
Q4 24
$1.16
$-0.99
Q3 24
$1.00
$-0.04
Q2 24
$0.85
$-0.04
Q1 24
$1.15
$-0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
JBSS
JBSS
TLRY
TLRY
Cash + ST InvestmentsLiquidity on hand
$2.4M
$291.6M
Total DebtLower is stronger
$28.8M
Stockholders' EquityBook value
$370.1M
$1.6B
Total Assets
$617.7M
$2.1B
Debt / EquityLower = less leverage
0.08×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
JBSS
JBSS
TLRY
TLRY
Q4 25
$2.4M
$291.6M
Q3 25
$714.0K
$264.8M
Q2 25
$585.0K
$256.4M
Q1 25
$1.3M
Q4 24
$336.0K
$252.2M
Q3 24
$442.0K
$280.1M
Q2 24
$484.0K
$260.5M
Q1 24
$377.0K
$225.9M
Total Debt
JBSS
JBSS
TLRY
TLRY
Q4 25
$28.8M
Q3 25
$29.8M
Q2 25
$14.6M
Q1 25
$5.8M
Q4 24
$6.0M
Q3 24
$6.2M
Q2 24
$6.4M
Q1 24
$6.6M
Stockholders' Equity
JBSS
JBSS
TLRY
TLRY
Q4 25
$370.1M
$1.6B
Q3 25
$362.8M
$1.5B
Q2 25
$360.7M
$1.5B
Q1 25
$346.6M
$2.7B
Q4 24
$325.6M
$3.5B
Q3 24
$310.8M
$3.5B
Q2 24
$322.6M
$3.4B
Q1 24
$321.8M
$3.4B
Total Assets
JBSS
JBSS
TLRY
TLRY
Q4 25
$617.7M
$2.1B
Q3 25
$598.7M
$2.1B
Q2 25
$597.6M
$2.1B
Q1 25
$590.0M
Q4 24
$545.3M
$4.2B
Q3 24
$519.4M
$4.3B
Q2 24
$515.6M
$4.2B
Q1 24
$491.9M
$4.2B
Debt / Equity
JBSS
JBSS
TLRY
TLRY
Q4 25
0.08×
Q3 25
0.08×
Q2 25
0.04×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.02×
Q2 24
0.02×
Q1 24
0.02×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
JBSS
JBSS
TLRY
TLRY
Operating Cash FlowLast quarter
$62.5M
$-8.5M
Free Cash FlowOCF − Capex
$40.0M
FCF MarginFCF / Revenue
12.7%
Capex IntensityCapex / Revenue
7.1%
Cash ConversionOCF / Net Profit
3.48×
TTM Free Cash FlowTrailing 4 quarters
$32.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
JBSS
JBSS
TLRY
TLRY
Q4 25
$62.5M
$-8.5M
Q3 25
$32.1M
$-1.3M
Q2 25
$36.5M
$-12.8M
Q1 25
$-25.9M
$-5.8M
Q4 24
$11.0M
$-40.7M
Q3 24
$8.9M
$-35.3M
Q2 24
$35.2M
$30.7M
Q1 24
$5.3M
$-15.4M
Free Cash Flow
JBSS
JBSS
TLRY
TLRY
Q4 25
$40.0M
Q3 25
$7.3M
Q2 25
$23.0M
$-19.1M
Q1 25
$-37.6M
$-20.2M
Q4 24
$-2.7M
$-46.2M
Q3 24
$-3.0M
$-42.0M
Q2 24
$24.4M
$21.0M
Q1 24
$-1.3M
$-24.9M
FCF Margin
JBSS
JBSS
TLRY
TLRY
Q4 25
12.7%
Q3 25
2.4%
Q2 25
8.6%
-8.5%
Q1 25
-14.4%
-10.9%
Q4 24
-0.9%
-21.9%
Q3 24
-1.1%
-21.0%
Q2 24
9.0%
9.1%
Q1 24
-0.5%
-13.2%
Capex Intensity
JBSS
JBSS
TLRY
TLRY
Q4 25
7.1%
Q3 25
8.3%
Q2 25
5.0%
2.8%
Q1 25
4.5%
7.8%
Q4 24
4.5%
2.6%
Q3 24
4.3%
3.4%
Q2 24
4.0%
4.2%
Q1 24
2.4%
5.1%
Cash Conversion
JBSS
JBSS
TLRY
TLRY
Q4 25
3.48×
Q3 25
1.72×
Q2 25
2.70×
Q1 25
-1.29×
Q4 24
0.81×
Q3 24
0.77×
Q2 24
3.52×
Q1 24
0.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

JBSS
JBSS

Sales Channel Directly To Consumer$263.2M84%
Sales Channel Commercial Ingredients$28.0M9%
Sales Channel Contract Packaging$23.6M8%

TLRY
TLRY

Adultuse Cannabis Products$62.4M29%
Other$59.2M27%
Beverage Alcohol Business$53.6M25%
International Cannabis Products$20.2M9%
Wellness Business$14.6M7%
Medical Cannabis Products$6.2M3%
Wholesale Cannabis Products$1.3M1%

Related Comparisons